IL6 and COVID-19: Tissue factor, fibrinogen, thrombin, angiotensin II, and inflammatory cytokines, such as tumor necrosis factor- (TNF-) α, transforming growth factor- (TGF-) β, interleukin- (IL-) 1, and IL-6, are elevated in patients with COVID-19, which activates the PI3K-Akt signaling pathway and induces platelet activation and formation, mediating a hypercoagulable state of blood during COVID-19 infection [40–43].